Regulus appoints Neil Gibson chief scientific officer
This article was originally published in Scrip
Regulus Therapeutics, a La Jolla, California-based biopharmaceutical company focused on the discovery and development of new medicines targeting microRNAs, has named Dr Neil Gibson chief scientific officer. In this role, he will be responsible for leading all of the company's R&D efforts. Dr Gibson joins from the oncology research unit at Pfizer, where he was most recently chief scientific officer and oncology therapeutic area head. He also held leadership roles in Pfizer's oncology business unit leadership team and in the global leadership team of Pfizer’s pharmatherapeutics organisation.